IP Library Granted Patent US 11,274,349
Granted Patent B2
US 11,274,349 · App. 16/335,605 · Granted Mar 15, 2022

Methods for diagnosing cancer

Inventors: Dolores Di Vizio (Los Angeles, CA); Valentina R. Minciacchi (Los Angeles, CA); Andrew Conley (Los Angeles, CA)
Assignee: Cedars-Sinai Medical Center
C12Q1/6886C12Q1/68C12Q1/6851C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,274,349
App. No.
16/335,605
Granted
Mar 15, 2022
Kind
B2
Abstract

Provided herein are methods for diagnosing cancer in a subject by determining the gene expression level of one or more genes in extracellular vesicles isolated from samples obtained from a subject.

Claims (12)

1. A method for determining the likelihood of cancer and treating the cancer in a subject in need thereof comprising:

obtaining results of levels of mRNA encoded by histone genes and E2F-target genes in extracellular vesicles isolated from a sample obtained from the subject, wherein

the histones are HIST1H3F, HIST1H3G, HIST1H2AJ, HIST1H2BM, HIST1H1B, HIST1H3B, HIST1H2AH, HIST1H3J, HIST1H2BI, HIST1H2BO and HIST1H2AI, and

the E2F targets are SPC24, CENPF, ARHGAP11B, CEP128, QPCTL, HM MR, HIST1H2BL, NDC80, KIF15, HMBS, ABCB6, HIST1H2BM, GUCY1B3, SYNGR4, RECQL4, CDCA7, TTK, CKAP2, BORA and CENPW; and

determining that the subject has an increased likelihood of having cancer when the sample from the subject comprises increased levels of the mRNAs encoded by the histone and E2F target genes relative to a reference value; and

administering an effective amount of a therapy selected from the group consisting of surgery, radiation, chemotherapy, immunotherapy, vaccine, and combinations thereof to treat the cancer to the subject having the increased likelihood of having cancer.

2. The method of claim 1 , wherein the extracellular vesicles are microvesicles, exosomes, large oncosomes or a combination thereof.

3. The method of claim 1 , wherein the sample is blood, plasma or combination thereof.

4. The method of claim 1 wherein the subject is human.

5. The method of claim 1 , wherein the reference value is the mean or median levels of the mRNA in a population of subjects that do not have cancer.

6. The method of claim 1 , wherein the reference value is the mean or median levels of the mRNA in a population of subjects that have cancer in remission.

7. The method of claim 1 , wherein the reference value is the mean or median levels of the mRNA obtained from the subject at a difference time point.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 7, 2022
From: CEDARS-SINAI MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061886/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2019
From: DI VIZIO, DOLORES; MINCIACCHI, VALENTINA R.; CONLEY, ANDREW
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 048664/0754 →
Continuity (2)
Provisional Application 62419302 · Nov 8, 2016
Related Publication 20190300966A1 · Oct 3, 2019
Cited By (1)
US 12,590,965